肾脏并发症：保护糖尿病血管系统的因素。 - Suppr

Suppr

超能文献

Kidney complications: factors that protect the diabetic vasculature.

作者信息

Rask-Madsen Christian, King George L

机构信息

Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA.

出版信息

Nat Med. 2010 Jan;16(1):40-1. doi: 10.1038/nm0110-40.

DOI:10.1038/nm0110-40

PMID:20057426

Abstract

摘要

相似文献

Kidney complications: factors that protect the diabetic vasculature.

Nat Med. 2010 Jan;16(1):40-1. doi: 10.1038/nm0110-40.

Vascular endothelial growth factor and diabetic nephropathy.

Int J Artif Organs. 1999 May;22(5):297-9.

Growth factors and diabetic complications.

Diabet Med. 1990 Jun;7(5):387-99. doi: 10.1111/j.1464-5491.1990.tb01413.x.

Down-regulation of angiogenic inhibitors: a potential pathogenic mechanism for diabetic complications.

Curr Diabetes Rev. 2005 May;1(2):183-96. doi: 10.2174/1573399054022839.

The relationship of autonomic neuropathy to other diabetic complications.

Diabet Med. 1993;10 Suppl 2:74S-76S. doi: 10.1111/j.1464-5491.1993.tb00205.x.

[Physiopathology of chronic complications of diabetes].

Rev Med Suisse Romande. 1993 Sep;113(9):703-6.

[Functional glomerular microangiopathy].

Journ Annu Diabetol Hotel Dieu. 1979:19-34.

Why do some diabetics develop severe microvascular complications?

J Diabet Complications. 1989 Jan-Mar;3(1):1-5. doi: 10.1016/0891-6632(89)90002-0.

Diabetic control and microvascular complications: the near-normoglycaemic experience.

Diabetologia. 1986 Oct;29(10):677-84. doi: 10.1007/BF00870275.

Studies on the clearance and tubular reabsorption of phosphates in diabetes mellitus and some of its complications.

Diabetologia. 1966 Nov;2(3):198-201. doi: 10.1007/BF01222071.

引用本文的文献

Diabetic retinopathy: A review on its pathophysiology and novel treatment modalities.

World J Methodol. 2024 Dec 20;14(4):95881. doi: 10.5662/wjm.v14.i4.95881.

Regeneration of glomerular metabolism and function by podocyte pyruvate kinase M2 in diabetic nephropathy.

JCI Insight. 2022 Mar 8;7(5):e155260. doi: 10.1172/jci.insight.155260.

The effects of synthetic orally administrated insulin nanoparticles in comparison to injectable insulin on the renal function markers of type 1- diabetic rats.

Iran J Basic Med Sci. 2020 Jun;23(6):810-818. doi: 10.22038/ijbms.2020.42292.9985.

Risk Factors Associated With the Development of Nephropathy 10 Years After Diagnosis in Taiwanese Children With Juvenile-Onset Type 1 Diabetes-A Cohort Study From the CGJDES.

Front Endocrinol (Lausanne). 2018 Aug 3;9:429. doi: 10.3389/fendo.2018.00429. eCollection 2018.

Diabetic nephropathy and hypertension in diabetes patients of sub-Saharan countries: a systematic review and meta-analysis.

BMC Res Notes. 2018 Aug 6;11(1):565. doi: 10.1186/s13104-018-3670-5.

Diabetic retinopathy: current understanding, mechanisms, and treatment strategies.

JCI Insight. 2017 Jul 20;2(14). doi: 10.1172/jci.insight.93751.

Mechanism of hypertension in diabetic nephropathy.

J Nephropharmacol. 2014 Jul 1;3(2):49-55. eCollection 2014.

TNFSF15 Inhibits Blood Retinal Barrier Breakdown Induced by Diabetes.

Int J Mol Sci. 2016 Apr 25;17(5):615. doi: 10.3390/ijms17050615.

Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy.

J Am Soc Nephrol. 2015 Aug;26(8):1889-904. doi: 10.1681/ASN.2014040350. Epub 2014 Dec 26.

Molecular mechanisms of diabetic vascular complications.

J Diabetes Investig. 2010 Jun 1;1(3):77-89. doi: 10.1111/j.2040-1124.2010.00018.x.

本文引用的文献

Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy.

Nat Med. 2009 Nov;15(11):1298-306. doi: 10.1038/nm.2052. Epub 2009 Nov 1.

Maintaining retinal astrocytes normalizes revascularization and prevents vascular pathology associated with oxygen-induced retinopathy.

Glia. 2010 Jan 1;58(1):43-54. doi: 10.1002/glia.20900.

Vascular endothelial growth factor and diabetic nephropathy.

Curr Diab Rep. 2008 Dec;8(6):470-6. doi: 10.1007/s11892-008-0081-3.

Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy.

Diabetologia. 2008 Sep;51(9):1574-80. doi: 10.1007/s00125-008-0989-9. Epub 2008 Apr 11.

VEGF inhibition and renal thrombotic microangiopathy.

N Engl J Med. 2008 Mar 13;358(11):1129-36. doi: 10.1056/NEJMoa0707330.

Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis.

Nat Med. 2007 Nov;13(11):1349-58. doi: 10.1038/nm1667. Epub 2007 Nov 4.

Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study.

Diabetes Care. 2007 Aug;30(8):1995-7. doi: 10.2337/dc06-2222. Epub 2007 May 16.

Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival.

J Am Soc Nephrol. 2006 Mar;17(3):724-35. doi: 10.1681/ASN.2005080810. Epub 2006 Jan 25.

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.

J Clin Invest. 2003 Mar;111(5):707-16. doi: 10.1172/JCI17423.

The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years.

Arch Ophthalmol. 1984 Apr;102(4):520-6. doi: 10.1001/archopht.1984.01040030398010.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验